Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
The objective of this study was to explore differences in outcomes between first-line R-B and R-CHOP/R-DHAP in transplant-eligible patients with MCL. A population-based cohort of 97 patients aged 18-65 years with stage II-IV MCL, consecutively treated with R-B was retrospectively identified at BC Ca...
Gespeichert in:
Veröffentlicht in: | Blood advances 2022-09, Vol.6 (18), p.5285-5294 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 5294 |
---|---|
container_issue | 18 |
container_start_page | 5285 |
container_title | Blood advances |
container_volume | 6 |
creator | Villa, Diego Hoster, Eva Hermine, Olivier Klapper, Wolfram Szymczyk, Michal Bosly, André Unterhalt, Michael Rimsza, Lisa M. Ramsower, Colleen A. Freeman, Ciara L. Scott, David W. Gerrie, Alina S. Savage, Kerry J. Sehn, Laurie H. Dreyling, Martin |
description | The objective of this study was to explore differences in outcomes between first-line R-B and R-CHOP/R-DHAP in transplant-eligible patients with MCL. A population-based cohort of 97 patients aged 18-65 years with stage II-IV MCL, consecutively treated with R-B was retrospectively identified at BC Cancer. Baseline characteristics, response rates, and outcomes were compared to the cohort of 232 MCL patients randomized to the R-CHOP/R-DHAP arm of the MCL Younger trial. The primary aim was to estimate the hazard ratio (HR) of the progression-free survival (PFS) comparison between both groups, adjusted for MCL International Prognostic Index (MIPI), Ki67 index, and blastoid/pleomorphic morphology. Secondary endpoints included response rate, event free survival, overall survival, and time to next treatment. Ann Arbor stage, lactate dehydrogenase, MIPI, blastoid morphology, and MCL35 assignments were similar between both groups. The overall response rate (ORR) to R-B was 90% (54% complete response [CR]); 77% of patients proceeded to autologous stem cell transplantation (ASCT) and 78% received maintenance rituximab (MR). The ORR to R-CHOP/R-DHAP was 94% (54% CR); 78% proceeded to ASCT and 2% received MR. There were no differences in PFS in unadjusted (HR 0.87 [95% CI 0.53-1.41], p=0.56) or adjusted (HR 0.79 [95% CI 0.45-1.37], p=0.40) comparisons. There were no clear differences in secondary endpoints in unadjusted or adjusted analyses. This retrospective adjusted comparison of two independent cohorts of younger patients with MCL suggests that R-B with ASCT and maintenance rituximab is a feasible and effective first-line treatment, with outcomes comparable to R-CHOP/R-DHAP with ASCT. |
doi_str_mv | 10.1182/bloodadvances.2022007371 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2652864950</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2473952922002464</els_id><sourcerecordid>2652864950</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-f236225b32cbe0f11152824fa139cbca62ba379165c22d76c2745d7e419f00ca3</originalsourceid><addsrcrecordid>eNqFUE1P3DAQtVCrgih_ofKRS6g9TuL1EVCBSiv10p4tf0x2jZJ4sR3o_vsa7ZaKU0_z9ea9mUcI5eyK8xV8tWOM3vhnMzvMV8AAGJNC8hNyBq0UjeqE_PCWgzolFzk_Msa47EWn4BM5FV0rFChxRuINzt5MSy5hRhoT3YbNtvExI3X7YpKxtd9Yk9HTMPvFlRBn-hLKlqZQlt9hMrYOaElmzrvRzKXBMWyCHZFOtarB4TjScT_ttnEyn8nHwYwZL47xnPy6-_bz9qFZ_7j_fnu9blwLbWkGED1AZwU4i2zgnHewgnYwXChnnenBGiEV7zsH4GXvQLadl9hyNTDmjDgnlwfeXYpPC-aip5BfLzEzxiVr6Cth36qOVejqAHUp5pxw0LtU30p7zZl-dVy_c1z_c7yufjmqLHZC_7b4198KuDkAsP76HDDp7AJWGh8SuqJ9DP9X-QMle5kf</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2652864950</pqid></control><display><type>article</type><title>Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Villa, Diego ; Hoster, Eva ; Hermine, Olivier ; Klapper, Wolfram ; Szymczyk, Michal ; Bosly, André ; Unterhalt, Michael ; Rimsza, Lisa M. ; Ramsower, Colleen A. ; Freeman, Ciara L. ; Scott, David W. ; Gerrie, Alina S. ; Savage, Kerry J. ; Sehn, Laurie H. ; Dreyling, Martin</creator><creatorcontrib>Villa, Diego ; Hoster, Eva ; Hermine, Olivier ; Klapper, Wolfram ; Szymczyk, Michal ; Bosly, André ; Unterhalt, Michael ; Rimsza, Lisa M. ; Ramsower, Colleen A. ; Freeman, Ciara L. ; Scott, David W. ; Gerrie, Alina S. ; Savage, Kerry J. ; Sehn, Laurie H. ; Dreyling, Martin</creatorcontrib><description>The objective of this study was to explore differences in outcomes between first-line R-B and R-CHOP/R-DHAP in transplant-eligible patients with MCL. A population-based cohort of 97 patients aged 18-65 years with stage II-IV MCL, consecutively treated with R-B was retrospectively identified at BC Cancer. Baseline characteristics, response rates, and outcomes were compared to the cohort of 232 MCL patients randomized to the R-CHOP/R-DHAP arm of the MCL Younger trial. The primary aim was to estimate the hazard ratio (HR) of the progression-free survival (PFS) comparison between both groups, adjusted for MCL International Prognostic Index (MIPI), Ki67 index, and blastoid/pleomorphic morphology. Secondary endpoints included response rate, event free survival, overall survival, and time to next treatment. Ann Arbor stage, lactate dehydrogenase, MIPI, blastoid morphology, and MCL35 assignments were similar between both groups. The overall response rate (ORR) to R-B was 90% (54% complete response [CR]); 77% of patients proceeded to autologous stem cell transplantation (ASCT) and 78% received maintenance rituximab (MR). The ORR to R-CHOP/R-DHAP was 94% (54% CR); 78% proceeded to ASCT and 2% received MR. There were no differences in PFS in unadjusted (HR 0.87 [95% CI 0.53-1.41], p=0.56) or adjusted (HR 0.79 [95% CI 0.45-1.37], p=0.40) comparisons. There were no clear differences in secondary endpoints in unadjusted or adjusted analyses. This retrospective adjusted comparison of two independent cohorts of younger patients with MCL suggests that R-B with ASCT and maintenance rituximab is a feasible and effective first-line treatment, with outcomes comparable to R-CHOP/R-DHAP with ASCT.</description><identifier>ISSN: 2473-9529</identifier><identifier>EISSN: 2473-9537</identifier><identifier>DOI: 10.1182/bloodadvances.2022007371</identifier><identifier>PMID: 35439293</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>autologous stem cell transplant ; bendamustine ; cytarabine ; mantle cell lymphoma ; rituximab ; transplant eligible</subject><ispartof>Blood advances, 2022-09, Vol.6 (18), p.5285-5294</ispartof><rights>2022 The American Society of Hematology</rights><rights>Copyright © 2022 American Society of Hematology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-f236225b32cbe0f11152824fa139cbca62ba379165c22d76c2745d7e419f00ca3</citedby><cites>FETCH-LOGICAL-c424t-f236225b32cbe0f11152824fa139cbca62ba379165c22d76c2745d7e419f00ca3</cites><orcidid>0000-0002-5835-9863 ; 0000-0001-7208-4117 ; 0000-0002-0358-5249 ; 0000-0002-4625-3009 ; 0000-0002-0749-1389 ; 0000-0002-0435-5947 ; 0000-0003-4727-1425</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35439293$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Villa, Diego</creatorcontrib><creatorcontrib>Hoster, Eva</creatorcontrib><creatorcontrib>Hermine, Olivier</creatorcontrib><creatorcontrib>Klapper, Wolfram</creatorcontrib><creatorcontrib>Szymczyk, Michal</creatorcontrib><creatorcontrib>Bosly, André</creatorcontrib><creatorcontrib>Unterhalt, Michael</creatorcontrib><creatorcontrib>Rimsza, Lisa M.</creatorcontrib><creatorcontrib>Ramsower, Colleen A.</creatorcontrib><creatorcontrib>Freeman, Ciara L.</creatorcontrib><creatorcontrib>Scott, David W.</creatorcontrib><creatorcontrib>Gerrie, Alina S.</creatorcontrib><creatorcontrib>Savage, Kerry J.</creatorcontrib><creatorcontrib>Sehn, Laurie H.</creatorcontrib><creatorcontrib>Dreyling, Martin</creatorcontrib><title>Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma</title><title>Blood advances</title><addtitle>Blood Adv</addtitle><description>The objective of this study was to explore differences in outcomes between first-line R-B and R-CHOP/R-DHAP in transplant-eligible patients with MCL. A population-based cohort of 97 patients aged 18-65 years with stage II-IV MCL, consecutively treated with R-B was retrospectively identified at BC Cancer. Baseline characteristics, response rates, and outcomes were compared to the cohort of 232 MCL patients randomized to the R-CHOP/R-DHAP arm of the MCL Younger trial. The primary aim was to estimate the hazard ratio (HR) of the progression-free survival (PFS) comparison between both groups, adjusted for MCL International Prognostic Index (MIPI), Ki67 index, and blastoid/pleomorphic morphology. Secondary endpoints included response rate, event free survival, overall survival, and time to next treatment. Ann Arbor stage, lactate dehydrogenase, MIPI, blastoid morphology, and MCL35 assignments were similar between both groups. The overall response rate (ORR) to R-B was 90% (54% complete response [CR]); 77% of patients proceeded to autologous stem cell transplantation (ASCT) and 78% received maintenance rituximab (MR). The ORR to R-CHOP/R-DHAP was 94% (54% CR); 78% proceeded to ASCT and 2% received MR. There were no differences in PFS in unadjusted (HR 0.87 [95% CI 0.53-1.41], p=0.56) or adjusted (HR 0.79 [95% CI 0.45-1.37], p=0.40) comparisons. There were no clear differences in secondary endpoints in unadjusted or adjusted analyses. This retrospective adjusted comparison of two independent cohorts of younger patients with MCL suggests that R-B with ASCT and maintenance rituximab is a feasible and effective first-line treatment, with outcomes comparable to R-CHOP/R-DHAP with ASCT.</description><subject>autologous stem cell transplant</subject><subject>bendamustine</subject><subject>cytarabine</subject><subject>mantle cell lymphoma</subject><subject>rituximab</subject><subject>transplant eligible</subject><issn>2473-9529</issn><issn>2473-9537</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqFUE1P3DAQtVCrgih_ofKRS6g9TuL1EVCBSiv10p4tf0x2jZJ4sR3o_vsa7ZaKU0_z9ea9mUcI5eyK8xV8tWOM3vhnMzvMV8AAGJNC8hNyBq0UjeqE_PCWgzolFzk_Msa47EWn4BM5FV0rFChxRuINzt5MSy5hRhoT3YbNtvExI3X7YpKxtd9Yk9HTMPvFlRBn-hLKlqZQlt9hMrYOaElmzrvRzKXBMWyCHZFOtarB4TjScT_ttnEyn8nHwYwZL47xnPy6-_bz9qFZ_7j_fnu9blwLbWkGED1AZwU4i2zgnHewgnYwXChnnenBGiEV7zsH4GXvQLadl9hyNTDmjDgnlwfeXYpPC-aip5BfLzEzxiVr6Cth36qOVejqAHUp5pxw0LtU30p7zZl-dVy_c1z_c7yufjmqLHZC_7b4198KuDkAsP76HDDp7AJWGh8SuqJ9DP9X-QMle5kf</recordid><startdate>20220927</startdate><enddate>20220927</enddate><creator>Villa, Diego</creator><creator>Hoster, Eva</creator><creator>Hermine, Olivier</creator><creator>Klapper, Wolfram</creator><creator>Szymczyk, Michal</creator><creator>Bosly, André</creator><creator>Unterhalt, Michael</creator><creator>Rimsza, Lisa M.</creator><creator>Ramsower, Colleen A.</creator><creator>Freeman, Ciara L.</creator><creator>Scott, David W.</creator><creator>Gerrie, Alina S.</creator><creator>Savage, Kerry J.</creator><creator>Sehn, Laurie H.</creator><creator>Dreyling, Martin</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5835-9863</orcidid><orcidid>https://orcid.org/0000-0001-7208-4117</orcidid><orcidid>https://orcid.org/0000-0002-0358-5249</orcidid><orcidid>https://orcid.org/0000-0002-4625-3009</orcidid><orcidid>https://orcid.org/0000-0002-0749-1389</orcidid><orcidid>https://orcid.org/0000-0002-0435-5947</orcidid><orcidid>https://orcid.org/0000-0003-4727-1425</orcidid></search><sort><creationdate>20220927</creationdate><title>Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma</title><author>Villa, Diego ; Hoster, Eva ; Hermine, Olivier ; Klapper, Wolfram ; Szymczyk, Michal ; Bosly, André ; Unterhalt, Michael ; Rimsza, Lisa M. ; Ramsower, Colleen A. ; Freeman, Ciara L. ; Scott, David W. ; Gerrie, Alina S. ; Savage, Kerry J. ; Sehn, Laurie H. ; Dreyling, Martin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-f236225b32cbe0f11152824fa139cbca62ba379165c22d76c2745d7e419f00ca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>autologous stem cell transplant</topic><topic>bendamustine</topic><topic>cytarabine</topic><topic>mantle cell lymphoma</topic><topic>rituximab</topic><topic>transplant eligible</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Villa, Diego</creatorcontrib><creatorcontrib>Hoster, Eva</creatorcontrib><creatorcontrib>Hermine, Olivier</creatorcontrib><creatorcontrib>Klapper, Wolfram</creatorcontrib><creatorcontrib>Szymczyk, Michal</creatorcontrib><creatorcontrib>Bosly, André</creatorcontrib><creatorcontrib>Unterhalt, Michael</creatorcontrib><creatorcontrib>Rimsza, Lisa M.</creatorcontrib><creatorcontrib>Ramsower, Colleen A.</creatorcontrib><creatorcontrib>Freeman, Ciara L.</creatorcontrib><creatorcontrib>Scott, David W.</creatorcontrib><creatorcontrib>Gerrie, Alina S.</creatorcontrib><creatorcontrib>Savage, Kerry J.</creatorcontrib><creatorcontrib>Sehn, Laurie H.</creatorcontrib><creatorcontrib>Dreyling, Martin</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood advances</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Villa, Diego</au><au>Hoster, Eva</au><au>Hermine, Olivier</au><au>Klapper, Wolfram</au><au>Szymczyk, Michal</au><au>Bosly, André</au><au>Unterhalt, Michael</au><au>Rimsza, Lisa M.</au><au>Ramsower, Colleen A.</au><au>Freeman, Ciara L.</au><au>Scott, David W.</au><au>Gerrie, Alina S.</au><au>Savage, Kerry J.</au><au>Sehn, Laurie H.</au><au>Dreyling, Martin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma</atitle><jtitle>Blood advances</jtitle><addtitle>Blood Adv</addtitle><date>2022-09-27</date><risdate>2022</risdate><volume>6</volume><issue>18</issue><spage>5285</spage><epage>5294</epage><pages>5285-5294</pages><issn>2473-9529</issn><eissn>2473-9537</eissn><abstract>The objective of this study was to explore differences in outcomes between first-line R-B and R-CHOP/R-DHAP in transplant-eligible patients with MCL. A population-based cohort of 97 patients aged 18-65 years with stage II-IV MCL, consecutively treated with R-B was retrospectively identified at BC Cancer. Baseline characteristics, response rates, and outcomes were compared to the cohort of 232 MCL patients randomized to the R-CHOP/R-DHAP arm of the MCL Younger trial. The primary aim was to estimate the hazard ratio (HR) of the progression-free survival (PFS) comparison between both groups, adjusted for MCL International Prognostic Index (MIPI), Ki67 index, and blastoid/pleomorphic morphology. Secondary endpoints included response rate, event free survival, overall survival, and time to next treatment. Ann Arbor stage, lactate dehydrogenase, MIPI, blastoid morphology, and MCL35 assignments were similar between both groups. The overall response rate (ORR) to R-B was 90% (54% complete response [CR]); 77% of patients proceeded to autologous stem cell transplantation (ASCT) and 78% received maintenance rituximab (MR). The ORR to R-CHOP/R-DHAP was 94% (54% CR); 78% proceeded to ASCT and 2% received MR. There were no differences in PFS in unadjusted (HR 0.87 [95% CI 0.53-1.41], p=0.56) or adjusted (HR 0.79 [95% CI 0.45-1.37], p=0.40) comparisons. There were no clear differences in secondary endpoints in unadjusted or adjusted analyses. This retrospective adjusted comparison of two independent cohorts of younger patients with MCL suggests that R-B with ASCT and maintenance rituximab is a feasible and effective first-line treatment, with outcomes comparable to R-CHOP/R-DHAP with ASCT.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35439293</pmid><doi>10.1182/bloodadvances.2022007371</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-5835-9863</orcidid><orcidid>https://orcid.org/0000-0001-7208-4117</orcidid><orcidid>https://orcid.org/0000-0002-0358-5249</orcidid><orcidid>https://orcid.org/0000-0002-4625-3009</orcidid><orcidid>https://orcid.org/0000-0002-0749-1389</orcidid><orcidid>https://orcid.org/0000-0002-0435-5947</orcidid><orcidid>https://orcid.org/0000-0003-4727-1425</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2473-9529 |
ispartof | Blood advances, 2022-09, Vol.6 (18), p.5285-5294 |
issn | 2473-9529 2473-9537 |
language | eng |
recordid | cdi_proquest_miscellaneous_2652864950 |
source | DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
subjects | autologous stem cell transplant bendamustine cytarabine mantle cell lymphoma rituximab transplant eligible |
title | Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T16%3A29%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bendamustine%20or%20high-dose%20cytarabine-based%20induction%20with%20rituximab%20in%20transplant-eligible%20mantle%20cell%20lymphoma&rft.jtitle=Blood%20advances&rft.au=Villa,%20Diego&rft.date=2022-09-27&rft.volume=6&rft.issue=18&rft.spage=5285&rft.epage=5294&rft.pages=5285-5294&rft.issn=2473-9529&rft.eissn=2473-9537&rft_id=info:doi/10.1182/bloodadvances.2022007371&rft_dat=%3Cproquest_cross%3E2652864950%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2652864950&rft_id=info:pmid/35439293&rft_els_id=S2473952922002464&rfr_iscdi=true |